Product Name :
KEAP1 Rabbit monoclonal antibody Background :
The nuclear factor-like 2 (NRF2) transcriptional activator binds antioxidant response elements (ARE) of target gene promoter regions to regulate expression of oxidative stress response genes. Under basal conditions, the NRF2 inhibitor INrf2 (also called KEAP1) binds and retains NRF2 in the cytoplasm where it can be targeted for ubiquitin-mediated degradation. Small amounts of constitutive nuclear NRF2 maintain cellular homeostasis through regulation of basal expression of antioxidant response genes. Following oxidative or electrophilic stress, KEAP1 releases NRF2, thereby allowing the activator to translocate to the nucleus and bind to ARE-containing genes. The coordinated action of NRF2 and other transcription factors mediates the response to oxidative stress. Altered expression of NRF2 is associated with chronic obstructive pulmonary disease (COPD). NRF2 activity in lung cancer cell lines directly correlates with cell proliferation rates, and inhibition of NRF2 expression by siRNA enhances anti-cancer drug-induced apoptosis.KEAP1 contains an amino terminal BTB/POZ domain and a carboxyl terminal KELCH domain. The KELCH domain is required for interaction with NRF2, and the BTB/POZ domain functions in binding Cul3 E3 ubiquitin ligase. Under normal conditions, the complex leads to the cytoplasmic sequestration and ubiquitin-mediated proteasomal degradation of NRF2. Electrophilic modification of KEAP1 leads to disassociation of the NRF2/KEAP1 complex. KEAP1 also targets the down regulation of NF-κB activity by targeting IKKβ degradation. Mutation of the corresponding KEAP1 gene is seen in lung cancer cases and can lead to uncontrolled activation of NRF2. Product :
Liquid in 50mM Tris-Glycine (pH 7.4), 0.15M NaCl, 50% Glycerol, 0.01% Sodium azide and 0.05% BSA. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
Recognizes endogenous levels of KEAP1 protein. Immunogen :
Recombinant protein of human Keap1 Conjugate :
Unconjugated Modification :
Unmodification

• 
  Western blot analysis of KEAP1 expression in Raw264.7 (A), Hela (B), A549 (C), C2C12 (D) whole cell lysates.
• 
  Immunohistochemical analysis of KEAP1 staining in human breast carcinoma formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.22). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.

---

Price/Size :

USD 368/1mg/vial

---

---

Tips: 

For phospho antibody, we provide phospho peptide（0.5mg) and non-phospho peptide(0.5mg).

---

Describe :

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.

---

Formula:

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.

---

Storage:

The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C. 

---

Note :

This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.

---